Skip to main content
. 2017 Sep 25;56(21):2887–2890. doi: 10.2169/internalmedicine.8791-16

Figure 2.

Figure 2.

Clinical course. Initially, 3 mg of lusutrombopag was administered each day from Day 1 to Day 5. The platelet count increased to 98,000/μL on Day 5, so the administration was discontinued. As a second treatment, the administration of lusutrombopag was restarted from Day 60 to Day 66. TACE: transcatheter arterial chemoembolization, RFA: percutaneous radiofrequency ablation